Key Takeaways Energy and healthcare sectors are gaining investor interest due to perceived resilience against inflation and geopolitical uncertainty. Chevron, UnitedHealth, and Constellation Brands exemplify strong sectoral performance, with favourable...
Key Takeaways The US is prioritising concise, swiftly implemented trade pacts with partners including Japan, the UK, Vietnam, and South Korea, shifting away from traditional voluminous free trade agreements. These...
Key Takeaways A proposed multibillion-pound deal between OpenAI and the UK government may provide nationwide access to advanced AI tools, potentially reshaping public service delivery. The initiative forms part of...
Key Takeaways Recent IPOs in crypto and tech sectors are exhibiting price behaviours similar to meme coins, heavily driven by social media hype and retail investor enthusiasm. Retail investors now...
Key Takeaways The US allocated $71.9 billion to foreign aid in 2023, prompting debate over redirecting a portion toward domestic equity investments. Investment models suggest that a 20% reallocation into...
Key Takeaways B2Gold is trading at a forward P/E of 9.05, significantly below the sector average despite strong fundamentals. Operational highlights include Q2 2025 gold production of 229,454 ounces and...
Key Takeaways Moderna’s mRNA platform supports a broad therapeutic pipeline, extending well beyond COVID-19 vaccines into oncology, rare diseases and cardiovascular treatments. Despite substantial late-stage assets and multiple phase 3...
Key Takeaways PDD Holdings, trading at roughly 8x enterprise value to free cash flow, appears undervalued compared to its strong growth profile. Pinduoduo and Temu together drive expansion, with Temu...
Key Takeaways Vertex Pharmaceuticals holds a dominant 95% share of the US cystic fibrosis (CF) market, fortified by Trikafta’s patent protection through 2037. The CF market is projected to grow...
Key Takeaways PROCEPT BioRobotics’ Aquablation therapy offers a minimally invasive and repeatable alternative for treating benign prostatic hyperplasia (BPH), distinguished by its precision and reduced complication rates. Regulatory milestones—including Category...
